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Letter to the Editors
Dear Editor,
Increasing awareness about attention-deficit hyper-
activity disorder (ADHD) – whether related to campaigns 
sponsored by medical associations, patient self-help groups 
or pharmaceutical companies – is associated with a desir-
able progressive increase in the number of patients being 
diagnosed and treated. However, there are concerns about 
overtreatment, especially in children and adolescents, which 
is often addressed by the media in alarming ways.
Stimulants are the first-line treatment for ADHD in 
school-age children, adolescents and adults. The recent 
increase in the sales of these pharmaceuticals in Brazil has 
directed the attention of the community to the possibility 
of overtreatment. To verify whether the total number of 
stimulants sold in Brazil in 2009 and 2010 correspond to 
a larger-than-expected number of patients with ADHD in 
treatment, we analyzed the available data from the only 
two pharmaceutical companies in the country that were 
marketing stimulants during that period. We estimated the 
number of individuals that would be under continuous treat-
ment considering that a patient would take one single pill 
per day (even for immediate-release methylphenidate 10 mg, 
which should be administered two or three times a day) for 
22 days per month for ten months per year. It is important to 
note that we considered the minimum number of days in use 
for an adequate treatment, which implies that all patients 
would withdraw from medications during the summer and 
on weekends. In 2009, 1,413,460 boxes of methylphenidate 
formulations were sold in Brazil, which represents 32,986,110 
pills. In 2010, 1,674,372 boxes of methylphenidate formula-
tions were sold in Brazil, which represents 40,585,870 pills 
(data provided by IMS Health Care Measurement). Using our 
very liberal definition of continuous treatment (1 pill per day, 
for 22 days per month, for 10 months per year), well under 
treatment guidelines, we calculated that up to 149,937 and 
184,481 individuals could be under continuous treatment in 
2009 and 2010, respectively.
We then calculated the expected number of individuals 
with ADHD in Brazil, taking into account the latest official 
population figures provided by IBGE (2010). Again, to perform 
an extremely conservative analysis, we considered the lowest 
prevalence estimate detected in a Brazilian epidemiological 
study (0.9%) (Goodman et al.1), even though recent meta-
analyses computed worldwide rates of ADHD approximately 
5.3% for youths and 2.5% for adults (Polanczyk et al.2; Simon 
et al.3). Using these very conservative estimates for ADHD in 
the population, at least 924,732 individuals are expected to 
be affected by ADHD in Brazil (Table 1).
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Table 1 The maximum number of patients under continuous treatment in 2009-2010 in Brazil and the expected number 
of individuals with ADHD based on very conservative prevalence estimates
Age range Brazilian Population* Estimated prevalence 
of ADHD
Estimated number of 
individuals with ADHD 
in Brazil
Estimated number of 
patients with ADHD 
under treatment in 
2009**
Estimated number of 
patients with ADHD 
under treatment in 
2010**
5 to 19 years old 49,127,006 0.9% 442,143 - -
20 to 59 years old 107,242,035 0.45% 482,589 - -
60 years old and more
20,590,599 Unknown - - -
TOTAL 924,732 149,937 184,481
*Data from IBGE (www.ibge.gov.br), 2010. **The numbers of pills sold in Brazil in 2009-2010 were 32,986,110 and 40,585,870. Treatment is considered 
receiving one pill per day (independent of the dosage or pharmaceutical preparation) for 22 days per month for 10 months per year.
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Thus, it is estimated that only 16.2-19.9% of individuals 
affected by ADHD in Brazil were receiving first line treatment 
for the disorder in 2009-2010, even given very conservative 
figures calculated by overestimating the number of individu-
als receiving continuous treatment and underestimating the 
number of individuals with ADHD. In fact, the real figure is 
likely even lower because these stimulants also have other, 
less frequent indications. However, it is important to note 
that approximately 30% of ADHD patients do not respond 
to stimulants and should be treated with other agents; fur-
thermore, not all ADHD patients require pharmacological 
interventions. However, our extremely conservative analyses 
certainly counter-balance any effects of these two aspects. 
Concerns that an excessive number of individuals may be 
treated with stimulants for ADHD in our country lack any 
scientific basis. Further educational campaigns are needed 
to identify the significant proportion of untreated individuals 
affected by ADHD in Brazil.
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